 Home > Active Ingredient News > Antitumor Therapy > Int J Cancer: The impact of neoadjuvant system therapy on the prognosis of gastrointestinal stromal tumors

Int J Cancer: The impact of neoadjuvant system therapy on the prognosis of gastrointestinal stromal tumors

 Last Update: 2021-03-20
 Source: Internet
 Author: User

Tags

all day allergy relief

all seeing eye

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Retrospective and one-arm prospective studies have reported that the use of the neoadjuvant drug imatinib in the treatment of gastrointestinal stromal tumors (GIST) can achieve certain clinical benefits.

Gastrointestinal stromal tumor

This study aims to compare the effects of neoadjuvant system therapy and early resection on the prognosis of GIST patients.

Researchers selected 16,308 patients who underwent limited GIST resections of the stomach, esophagus, small intestine, and colon from the National Cancer Database (2004-2016).

Overall survival rate of the two groups

865 (5.

R0 resection rate of the two groups

Patients in the NAT group had larger tumors and higher mitotic index.

Receiving NAT treatment for more than 3 months is associated with significant survival benefits (weighted HR 0.

Although the risk of NAT patients is higher, this analysis shows that neoadjuvant system therapy for localized GIST patients is associated with a moderate survival benefit and a lower 90-day postoperative mortality rate, and does not affect the possibility of R0 resection.

Original source:

Marqueen Kathryn E,Moshier Erin,Buckstein Michael et al.

org/10.
1002/ijc.
33536">Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score weighted analysis in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.